Resources Repository
-
Resource PackWeb Portal, Teaching Resource 2018Resource Pack: Mental Health and Modeling
This resource pack, curated by the Center for Health Decision Science, features resources on modeling …
This resource pack, curated by the Center for Health Decision Science, features resources on modeling approaches applied to mental health. We aim to provide an overview of different techniques to guide researchers and practitioners in applying decision science and economic modeling to this public health challenge. More specifically, this resource pack contains review articles comparing different modeling techniques in the evaluation of treatments for depression, bipolar disorder and schizophrenia. The majority of articles in this…
State-Transition | North America | Mental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Health/Medicine | Europe -
ReportPublication 2017Underestimated Cost of the Opioid Crisis
This report on the opioid public health crisis was released by the White House Council …
This report on the opioid public health crisis was released by the White House Council on Economic Advisors (CEA) in November 2017. It corrects previous estimates of related costs by adding the value of the associated deaths. Earlier estimates focused on medical and other expenditures, while the new report also includes estimates of the value that individuals place on reducing their own risks of premature mortality. The report notes that, in 2015, over 33,000 Americans…
Benefit-Cost Analysis | North America | Mental Health | Preferences/Values | Costing Methods | Chronic Disease/Risk | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
State-Transition | North America | Mental Health | Cost-Effectiveness Analysis | Health/Medicine